ASCO 2017 Bladder Cancer

Viewing 1-20 of 26 articles

ASCO 2017: Astellas and Seattle Genetics Announce Updated Enfortumab Vedotin Phase 1 Data in Metastatic Urothelial Cancer

ASCO 2017: The clinical role of purified protein derivative skin test reaction in patients with non-muscle invasive bladder cancer treated with bacillus-Calmette Guerin

ASCO 2017: Cabazitaxel in patients with locally advanced or metastatic transitional cell carcinoma who developed disease progression within 12 months of platinum based chemotherapy: Results of a phase II trial—CAB-B1.

ASCO 2017: Effectiveness of the Moreau strain of Bacillus Calmette-Guerin (BCG) for nonmuscle invasive bladder cancer

ASCO 2017: Survival outcomes in elderly patients with muscle invasive bladder cancer: An analysis of the National Cancer Database

ASCO 2017: Comprehensive molecular characterization and analysis of muscle-invasive urothelial carcinomas

ASCO 2017: Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: Preliminary phase I/II results of ECHO-202/KEYNOTE-037

ASCO 2017: Bladder Cancer: 'Novel' Becomes the Norm

ASCO 2017: Intra-patient heterogeneity in urothelial cancer circulating tumor cells and PDL1 expression to identify biomarkers of response and new therapeutic targets

ASCO 2017: Comparison of somatic mutation profiles from cell free DNA versus tissue in metastatic urothelial carcinoma

ASCO 2017: Immune response results from vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase 2 trial in patients with non-muscle invasive bladder cancer (NMIBC)

ASCO 2017: Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer

ASCO 2017: Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045

ASCO 2017: Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study

ASCO 2017: Health-related quality of life as a marker of treatment benefit with nivolumab in platinum-refractory patients with metastatic or unresectable urothelial carcinoma from CheckMate 275

ASCO 2017: Phase 3 KEYNOTE-361 trial: Pembrolizumab with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer

ASCO 2017: Predictors of urinary diversion choice in patients with bladder cancer in integrated care settings

ASCO 2017: Phase I/II trial of cetuximab with 5-fluorouracil and mitomycin C concurrent with radiotherapy in patients with muscle invasive bladder cancer

ASCO 2017: Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC)

ASCO 2017: Management Strategies for Nonurothelial Bladder Cancer

1
2